Circassia

News
Lungs-16-9

Circassia gets dual boost for US COPD drugs

UK biotech Circassia has had two key decisions go in its favour with FDA, as the company continues with its efforts to rebuild its business after a series of disastrous allergy drug trial f

Views & Analysis
circassia

Circassia a cautionary tale for UK biotech, says Grainger

The UK biotech company is putting its huge failure in allergy treatment behind it.  But British venture capital leader David Grainger is highly critical of the company’s execs, and says lessons need to be learnt.